Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer

Ismet Sarikaya, Stephen P Povoski, Osama H Al-Saif, Ergun Kocak, Mark Bloomston, Steven Marsh, Zongjian Cao, Douglas A Murrey, Jun Zhang, Nathan C Hall, Michael V Knopp, Edward W Martin Jr, Ismet Sarikaya, Stephen P Povoski, Osama H Al-Saif, Ergun Kocak, Mark Bloomston, Steven Marsh, Zongjian Cao, Douglas A Murrey, Jun Zhang, Nathan C Hall, Michael V Knopp, Edward W Martin Jr

Abstract

Background: The purpose of this study was to combine intraoperative gamma probe (GP) detection with preoperative fluorine 18-fluoro-2-deoxy-glucose positron emission tomography (18F FDG-PET) imaging in order to improve detection of tumor recurrence in colorectal cancer (CRC) patients.

Methods: Twenty-one patients (12 females, 9 males) with a mean age of 54 years (range 31-78) were enrolled. Patients were suspected to have recurrent CRC by elevated CEA (n = 11), suspicious CT findings (n = 1), and clinically suspicious findings (n = 9). Preoperative FDG-PET scan and intraoperative GP study were performed in all patients. Mean time interval between preoperative FDG-PET scan and surgery was 16 days (range 1-41 days) in 19 patients. For intraoperative GP studies, 19 patients were injected with a dose of 10-15 mCi 18F FDG at approximately 30 minutes before the planned surgery time. In two patients, the intraoperative GP study was performed immediately after preoperative FDG-PET scan.

Results: Preoperative FDG-PET and intraoperative GP detected 48 and 45 lesions, respectively. A total of 50 presumed site of recurrent disease from 20 patients were resected. Thirty-seven of 50 presumed sites of recurrent disease were histological-proven tumor positive and 13 of 50 presumed sites of recurrent disease were histological-proven tumor negative. When correlated with final histopathology, the number of true positive lesions and false positive lesions by preoperative FDG-PET and intraoperative GP were 31/9 and 35/8, respectively. Both preoperative FDG-PET and intraoperative GP were true positive in 29 lesions. Intraoperative GP detected additional small lesions in the omentum and pelvis which were not seen on preoperative FDG-PET scan. FDG-PET scan demonstrated additional liver metastases which were not detected by intraoperative GP. Preoperative FDG-PET detected distant metastasis in the lung in one patient. The estimated radiation dose received by a surgeon during a single 18F FDG GP surgery was below the occupational limit.

Conclusion: The combined use of preoperative FDG-PET and intraoperative GP is potentially helpful to the surgeon as a roadmap for accurately locating and determining the extent of tumor recurrence in patients with CRC. While intraoperative GP appears to be more sensitive in detecting the extent of abdominal and pelvic recurrence, preoperative FDG-PET appears to be more sensitive in detecting liver metastases. FDG-PET is also a valuable method in detecting distant metastases.

Figures

Figure 1
Figure 1
Location of the lesions detected by PET and GP.
Figure 2
Figure 2
PET/CT fusion image on transaxial section demonstrates a hypermetabolic lesion (SUVmax : 8.2, Patient number 14) in the segment 6 of the liver (arrow) which could not be detected by GP. Final pathology was consistent with CRC metastasis.

References

    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.
    1. Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Jr, Pemberton JH, Wolff BG. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet. 1992;174:27–32.
    1. Cass AW, Million RR, Pfaff WW. Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer. 1976;37:2861–2865. doi: 10.1002/1097-0142(197606)37:6<2861::AID-CNCR2820370643>;2-3.
    1. Olson RM, Perencevich NP, Malcolm AW, Chaffey JT, Wilson RE. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer. 1980;45:2969–2974. doi: 10.1002/1097-0142(19800615)45:12<2969::AID-CNCR2820451214>;2-7.
    1. Turk PS, Wanebo HJ. Results of surgical treatment of nonhepatic recurrence of colorectal carcinoma. Cancer. 1993;15:4267–4277. doi: 10.1002/1097-0142(19930615)71:12+<4267::AID-CNCR2820711816>;2-O.
    1. Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer. 1984;53:1354–1362. doi: 10.1002/1097-0142(19840315)53:6<1354::AID-CNCR2820530623>;2-J.
    1. Welch JP, Donaldson GA. Detection and treatment of recurrent cancer of the colon and rectum. Am J Surg. 1978;135:505–511. doi: 10.1016/0002-9610(78)90028-4.
    1. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer. 1974;34:1278–1292. doi: 10.1002/1097-0142(197410)34:4<1278::AID-CNCR2820340440>;2-F.
    1. Rao AR, Kagan AR, Chan PM, Gilbert HA, Nussbaum H, Hintz BL. Patterns of recurrence following curative resection alone for adenocarcinoma of the rectum and sigmoid colon. Cancer. 1981;48:1492–1495. doi: 10.1002/1097-0142(19810915)48:6<1492::AID-CNCR2820480636>;2-K.
    1. Rich T, Gunderson LL, Lew R, Galdibini JJ, Cohen AM, Donaldson G. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer. 1983;52:1317–1329. doi: 10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>;2-6.
    1. Zervos EE, Badgwell BD, Burak WE, Jr, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery. 2001;130:636–643. doi: 10.1067/msy.2001.116919.
    1. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, Peeters M, Penninckx F, Filez L, Bleichrodt RP, Mortelmans L. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET) Eur J Cancer. 2001;37:862–869. doi: 10.1016/S0959-8049(01)00049-1.
    1. Maldonado A, Sancho F, Cerdan J, Lozano A, Mohedano N, Jimenez J, Moya F, Zomeno M. 16. FDG-PET in the Detection of Recurrence in Colorectal Cancer Based on Rising CEA Level. Experience in 72 Patients. Clin Positron Imaging. 2000;3:170. doi: 10.1016/S1095-0397(00)00082-0.
    1. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319–323. doi: 10.1097/00000658-199803000-00001.
    1. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med. 2001;28:1758–1765. doi: 10.1007/s002590100646.
    1. Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res. 2001;21:1375–1378.
    1. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW, Kodner IJ, Read TE. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000;43:759–767. doi: 10.1007/BF02238010.
    1. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, Greiss HB, Hofer GA. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503–511. doi: 10.1001/archsurg.134.5.503.
    1. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, Fleshman JW, Read TE, Philpott GW, Kodner IJ. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997;4:613–620. doi: 10.1007/BF02303744.
    1. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK, Jr, Chapman WC, Pinson CW. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196–1201.
    1. Staib L, Schirrmeister H, Reske SN, Beger HG. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg. 2000;180:1–5. doi: 10.1016/S0002-9610(00)00406-2.
    1. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177–1189.
    1. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, Emi T, Phelps ME. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol. 1998;16:2113–2125.
    1. Lange MK, Martin EW., Jr Monoclonal antibodies in imaging and therapy of colorectal cancer. World J Surg. 1991;15:617–622. doi: 10.1007/BF01789208.
    1. Cohen AM, Martin EW, Jr, Lavery I, Daly J, Sardi A, Aitken D, Bland K, Mojzisik C, Hinkle G. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg. 1991;126:349–352.
    1. Nieroda CA, Mojzisik C, Hinkle G, Thurston MO, Martin EW., Jr Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect Prev. 1991;15:225–229.
    1. Nieroda CA, Mojzisik C, Sardi A, Ferrara PJ, Hinkle G, Thurston MO, Martin EW., Jr Radioimmunoguided surgery in primary colon cancer. Cancer Detect Prev. 1990;14:651–656.
    1. Desai DC, Arnold M, Saha S, Hinkle G, Soble D, Fry J, DePalatis LR, Mantil J, Satter M, Martin EW. Correlative Whole-Body FDG-PET and Intraoperative Gamma Detection of FDG Distribution in Colorectal Cancer. Clin Positron Imaging. 2000;3:189–196. doi: 10.1016/S1095-0397(00)00052-2.
    1. Zervos EE, Desai DC, DePalatis LR, Soble D, Martin EW. 18F-labeled fluorodeoxyglucose positron emission tomography-guided surgery for recurrent colorectal cancer: a feasibility study. J Surg Res. 2001;1:9–13. doi: 10.1006/jsre.2001.6092.
    1. Essner R, Hsueh EC, Haigh PI, Glass EC, Huynh Y, Daghighian F. Application of an [(18)F]fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy. J Surg Res. 2001;96:120–126. doi: 10.1006/jsre.2000.6069.
    1. Martin EW, Jr, Thurston MO. Intraoperative radioimmunodetection. Semin Surg Oncol. 1998;15:205–208. doi: 10.1002/(SICI)1098-2388(199812)15:4<205::AID-SSU2>;2-S.
    1. Arnold MW, Hitchcock CL, Young DC, Burak WE, Jr, Bertsch DJ, Martin EW., Jr Intra-abdominal patterns of disease dissemination in colorectal cancer identified using radioimmunoguided surgery. Dis Colon Rectum. 1996;39:509–513. doi: 10.1007/BF02058702.
    1. Cote RJ, Houchens DP, Hitchcock CL, Saad AD, Nines RG, Greenson JK, Schneebaum S, Arnold MW, Martin EW., Jr Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49. Cancer. 1996;15:613–620. doi: 10.1002/(SICI)1097-0142(19960215)77:4<613::AID-CNCR5>;2-H.
    1. Arnold MW, Schneebaum S, Martin EW., Jr Radioimmunoguided Surgery in the Treatment and Evaluation of Rectal Cancer Patients. Cancer Control. 1996;3:42–45.
    1. Arnold MW, Young DC, Hitchcock CL, Schneebaum S, Martin EW., Jr Radioimmunoguided surgery in primary colorectal carcinoma: an intraoperative prognostic tool and adjuvant to traditional staging. Am J Surg. 1995;170:315–318. doi: 10.1016/S0002-9610(99)80295-5.
    1. Schneebaum S, Arnold MW, Houchens DP, Greenson JK, Cote RJ, Hitchcock CL, Young DC, Mojzisik CM, Martin EW., Jr The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer. 1995;75:2809–2817. doi: 10.1002/1097-0142(19950615)75:12<2809::AID-CNCR2820751205>;2-0.
    1. Arnold MW, Schneebaum S, Berens A, Mojzisik C, Hinkle G, Martin EW., Jr Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery. 1992;112:624–629. discussion 629–630.
    1. La Valle GJ, Chevinsky A, Martin EW., Jr Impact of Radioimmunoguided Surgery. Semin Surg Oncol. 1991;7:167–170. doi: 10.1002/ssu.2980070310.
    1. Nieroda CA, Mojzisik C, Sardi A, Ferrara P, Hinkle G, Thurston MO, Martin EW., Jr The impact of radioimmunoguided surgery (RIGS) on surgical decision-making in colorectal cancer. Dis Colon Rectum. 1989;32:927–932. doi: 10.1007/BF02552267.
    1. Martin EW, Jr, Mojzisik CM, Hinkle GH, Jr, Sampsel J, Siddiqi MA, Tuttle SE, Sickle-Santanello B, Colcher D, Thurston MO, Bell JG. Radioimmunoguided surgery using monoclonal antibody. Am J Surg. 1988;156:386–392. doi: 10.1016/S0002-9610(88)80193-4.
    1. Martin DT, Hinkle GH, Tuttle S, Olsen J, Nabi H, Houchens D, Thurston M, Martin EW., Jr Intraoperative radioimmunodetection of colorectal tumor with a hand-held radiation detector. Am J Surg. 1985;150:672–675. doi: 10.1016/0002-9610(85)90405-2.
    1. Aitken DR, Hinkle GH, Thurston MO, Tuttle SE, Martin DT, Olsen J, Haagensen DE, Jr, Houchens D, Martin EW., Jr A gamma-detecting probe for radioimmune detection of CEA-producing tumors. Successful experimental use and clinical case report. Dis Colon Rectum. 1984;27:279–282. doi: 10.1007/BF02555625.
    1. Barber HB, Barrett HH, Woolfenden JM, Myers KJ, Hickernell TS. Comparison of in vivo scintillation probes and gamma cameras for detection of small, deep tumours. Phys Med Biol. 1989;34:727–739. doi: 10.1088/0031-9155/34/6/008.
    1. Gutman F, Alberini JL, Wartski M, Vilain D, Le Stanc E, Sarandi F, Corone C, Tainturier C, Pecking AP. Incidental colonic focal lesions detected by FDG PET/CT. AJR. 2005;185:495–500. doi: 10.2214/AJR.04.1654.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe